| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/04/2002 | WO2002026704A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | WO2002026279A1 E-ptfe foil impregnated with an encapsulated bioactive substance |
| 04/04/2002 | WO2002026256A1 Excessive antibody production inhibitors, process for producing the same and method of using the same |
| 04/04/2002 | WO2002026224A2 Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
| 04/04/2002 | WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | WO2002014281A8 Pyridine derivatives as inhibitors of p38 |
| 04/04/2002 | WO2002006248A3 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 04/04/2002 | WO2002004421A3 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 04/04/2002 | WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor |
| 04/04/2002 | WO2001097837A8 Solubilised protein vaccines |
| 04/04/2002 | WO2001097795A3 Systems and methods for treating a mucosal surface |
| 04/04/2002 | WO2001096587A8 Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
| 04/04/2002 | WO2001094347A8 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 04/04/2002 | WO2001094301A3 Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
| 04/04/2002 | WO2001093893A3 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 04/04/2002 | WO2001092320A3 Use a high-molecular-weight extracellular haemoglobin as blood substitute |
| 04/04/2002 | WO2001090079A3 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists |
| 04/04/2002 | WO2001089451A3 Protease inhibitors |
| 04/04/2002 | WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/04/2002 | WO2001087263A3 Delivery systems for treatment of vascular disease |
| 04/04/2002 | WO2001085980A3 Enzymatic assays for screening anti-cancer agents |
| 04/04/2002 | WO2001085227A3 Nitric oxide-releasing metallic medical devices |
| 04/04/2002 | WO2001085100A3 Vasodilator-thrombolytic fusion proteins and conjugates |
| 04/04/2002 | WO2001070678A3 Substituted biphenyl derivatives |
| 04/04/2002 | WO2001064643A3 Benzamides and related inhibitors of factor xa |
| 04/04/2002 | WO2001047507A3 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 04/04/2002 | WO2001034182A3 Composition for treating respiratory tract infections containing menthol, eucalyptol and an alpha-amylase |
| 04/04/2002 | US20020040128 Carbohydrate-blood protein complex for us as an oxygen transporter |
| 04/04/2002 | US20020040043 Amidino derivatives and their use as thrombin inhibitors |
| 04/04/2002 | US20020040012 A synthetic pentasaccharide which is a selective inhibitor of faxtor xa, acting via antithrombin III |
| 04/04/2002 | US20020040003 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus |
| 04/04/2002 | US20020039577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes |
| 04/04/2002 | DE10044792A1 Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung Substituted Phenylcyclohexancarbonsäureamide and their use |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2423919A1 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | CA2423889A1 Methods and compositions for screening modulators of lipid kinases |
| 04/04/2002 | CA2423704A1 G-protein coupled receptors |
| 04/04/2002 | CA2423474A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | CA2423305A1 Compounds useful in the treatment of inflammatory diseases |
| 04/04/2002 | CA2423141A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 04/04/2002 | CA2422873A1 Piperazin-2-one amides as inhibitors of factor xa |
| 04/04/2002 | CA2420851A1 .alpha.-substituted .beta.-aminoethyl phosphonates |
| 04/04/2002 | CA2420475A1 Ige receptor antagonists |
| 04/04/2002 | CA2420045A1 Melanocortin receptor ligands |
| 04/03/2002 | EP1193248A1 Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use |
| 04/03/2002 | EP1192951A2 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound |
| 04/03/2002 | EP1192266A2 Complement-resistant non-mammalian dna viruses and uses thereof |
| 04/03/2002 | EP1192261A1 22025, a novel human cyclic nucleotide phosphodiesterase |
| 04/03/2002 | EP1192257A2 Human regulators of intracellular phosphorylation |
| 04/03/2002 | EP1192250A2 Human rna metabolism proteins (rmep) |
| 04/03/2002 | EP1192249A1 47 human secreted proteins |
| 04/03/2002 | EP1192243A1 Method for enhancing hematopoiesis |
| 04/03/2002 | EP1192187A1 Heparin compositions that inhibit clot associated coagulation factors |
| 04/03/2002 | EP1192171A1 48 human secreted proteins |
| 04/03/2002 | EP1192170A1 Propargyl phenyl ether a2a receptor agonists |
| 04/03/2002 | EP1192169A2 C-pyrazole a2a receptor agonists |
| 04/03/2002 | EP1192156A1 Bispidine compounds useful in the treatment of cardiac arrhythmias |
| 04/03/2002 | EP1192134A2 Processes for the preparation of (r)-g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol |
| 04/03/2002 | EP1192132A2 Serine protease inhibitors |
| 04/03/2002 | EP1191948A2 High dose radionuclide complexes for bone marrow suppression |
| 04/03/2002 | EP1191940A1 Tumor necrosis factor receptor 5 |
| 04/03/2002 | EP1191932A1 Production of agglomerates of inogatran and the compound inogatran anhydrate |
| 04/03/2002 | EP1191931A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
| 04/03/2002 | EP0927038B1 P1, p4-dithio-p2,p3-monochloromethylene 5', 5'''-diadenosine p1, p4-tetraphosphate as antithrombotic agent |
| 04/03/2002 | EP0865281B1 Naphthyl-substituted benzimidazole derivatives as anticoagulants |
| 04/03/2002 | CN1343217A New amidinobenzylamine derivatives and their use as thrombin inhibitors |
| 04/03/2002 | CN1343120A Essential fatty acids in prevention of cardiovascular events |
| 04/03/2002 | CN1342490A Process for preparing staltic-antagic medicine to treat trauma |
| 04/02/2002 | US6365749 Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| 04/02/2002 | US6365617 Indole and indazole urea-peptoids as thrombin receptor antagonists |
| 04/02/2002 | US6365611 Pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same |
| 04/02/2002 | US6365587 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 04/02/2002 | US6365583 Methods to enhance white blood cell count |
| 04/02/2002 | US6365572 For therapy of diseases related to increased or unwanted synthesis of basement membranes such as diabetes mellitus; atherosclerosis; cancer; diabetic retinopathia; fibroplasia retrolentalis; or psoriasis, rheumatoic arthritis |
| 04/02/2002 | US6365389 Human protein kinase H2LAU20 |
| 04/02/2002 | US6365186 Combination therapy for treating hypercholesterolemia |
| 04/02/2002 | US6365155 Monoclonal antibody, antibody fragment, mixture or derivative thereof, which binds to ancrod and inhibits its activity |
| 04/02/2002 | CA2182483C Il-3 variant hematopoiesis fusion protein |
| 04/02/2002 | CA2086835C Tissue plasminogen activator variants with decreased clearance |
| 04/02/2002 | CA2053340C Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| 04/02/2002 | CA1341354C Anticoagulant peptide alcohols |
| 03/29/2002 | WO2003045398A1 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024923A1 Polypeptide having phospholipase a2 actiivty |
| 03/28/2002 | WO2002024909A2 Receptor nucleic acids and polypeptides |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024754A1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 03/28/2002 | WO2002024751A1 Dextran-hemoglobin conjugates as blood substitutes |
| 03/28/2002 | WO2002024711A1 Novel thiazole bicyclic compounds |
| 03/28/2002 | WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | WO2002024694A1 Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
| 03/28/2002 | WO2002024690A2 Efficient process for the preparation of a factor xa inhibitor |
| 03/28/2002 | WO2002024674A1 Benzoic acid derivatives and uses thereof |
| 03/28/2002 | WO2002024672A2 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/28/2002 | WO2002024667A1 4-amino-quinazolines |
| 03/28/2002 | WO2002024666A2 4-amino-quinazolines |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024303A1 Blood centrifuge cup having a replaceable compartment for filter support |
| 03/28/2002 | WO2002024239A1 Method and hemostatic patch for effecting local hemostasis |
| 03/28/2002 | WO2002024215A2 Method for using activated protein c for the treatment of coagulation-associated disorders |